FOCAL POINT  (Left to right) Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto, Yasuhito Onodera, Yukari Kado, Hisataka Sabe, and colleagues investigate how the metabolic mevalonate pathway enhances the invasiveness of some, but not all, breast cancer cell lines. The researchers find that the pathway promotes the prenylation and membrane trafficking activity of Rab11b (red), which delivers the Arf6 GTPase (green) to the plasma membrane where it can be activated to promote cancer cell invasion and drug resistance. The mevalonate pathway only enhances the invasiveness of cell lines that overexpress Arf6 signaling proteins, but patients whose tumors show up-regulation of both Arf6 and mevalonate pathway components have poor long-term survival rates. / PHOTOS COURTESY OF THE AUTHORS

FOCAL POINT  (Left to right) Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto, Yasuhito Onodera, Yukari Kado, Hisataka Sabe, and colleagues investigate how the metabolic mevalonate pathway enhances the invasiveness of some, but not all, breast cancer cell lines. The researchers find that the pathway promotes the prenylation and membrane trafficking activity of Rab11b (red), which delivers the Arf6 GTPase (green) to the plasma membrane where it can be activated to promote cancer cell invasion and drug resistance. The mevalonate pathway only enhances the invasiveness of cell lines that overexpress Arf6 signaling proteins, but patients whose tumors show up-regulation of both Arf6 and mevalonate pathway components have poor long-term survival rates.

PHOTOS COURTESY OF THE AUTHORS

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal